Menu
Comprehensive
AI-enabled assessment of plaque quantity and composition
Accurate
High correlation to IVUS plaque volumes to empower clinical decisions
Actionable
Enables clinicians to determine targeted preventive therapies 2,3
1 Narula et al. Eur Heart J 2024. https://doi.org/10.1093/ehjci/jeae115)
2 Rinehart, Sarah et al. JSCAI March 26, 2024.
https:// www.jscai.org/articles/S2772-9303(24)00003-6/fulltext?dgcid=raven_jbs_etoc_email
3 Tzimas, et al. JACC 2023. https://doi.org/10.1016/j.jcmg.2023.05.011
† When FFRCT is performed.
Discuss HeartFlow Plaque Analysis with one of our experts.
Discuss HeartFlow Plaque Analysis with one of our experts.
Comprehensive
AI-enabled assessment of plaque quantity and composition
Accurate
High correlation to IVUS plaque volumes to empower clinical decisions
Actionable
Enables clinicians to determine targeted preventive therapies 2,3
1 Narula et al. Eur Heart J 2024. https://doi.org/10.1093/ehjci/jeae115)
2 Rinehart, Sarah et al. JSCAI March 26, 2024.
https:// www.jscai.org/articles/S2772-9303(24)00003-6/fulltext?dgcid=raven_jbs_etoc_email
3 Tzimas, et al. JACC 2023. https://doi.org/10.1016/j.jcmg.2023.05.011
† When FFRCT is performed.
Transforming Precision Coronary Care
FFRCT Analysis
RoadMap™ Analysis
Plaque Analysis
Mockup for visualization and actual appearance may change and clinical information is for illustrative purposes only. Available as part of HeartFlow software update this Fall for sites with HeartFlow Plaque Analysis. Select features pending regulatory clearance may only be available at a later date.
HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？